Trakatellis A, Dimitriadou A, Exindari M, Christodoulou D, Malissiovas N, Antoniadis A, Haitoglou K
Department of Biochemistry, Medical School, Aristotle University of Thessaloniki, Greece.
Postgrad Med J. 1994;70 Suppl 1:S89-92.
Measurements of serine hydroxymethyltransferase (SHMT) in resting lymphocyte cultures showed that the level of activity of this enzyme is very low. Under the influence of mitogenic stimuli serine hydroxymethyltransferase activity is induced 5-20-fold. Addition in the cultures of 4-deoxypyridoxine (dB6), a potent antagonist of vitamin B6 coenzymes, concurrently with the mitogen, inhibits the induction of SHMT. Separate addition in the cultures of four anti-proliferative (AP) and immunosuppressive (IMS) agents, namely actinomycin, cytarabine, asparaginase and cyclosporine, led to the following observations. (1) The AP and IMS agents produce a decrease in the mitogen-induced activity of SHMT. The higher the concentration of the AP/IMS compound, the greater the decrease of enzymatic activity. (2) When a AP/IMS agent is combined with dB6 its effect on SHMT is considerably greater. (3) Ineffective concentrations of AP/IMS agents become effective when combined with dB6. (4) The observed changes in SHMT activity are not, as one would expect, the same in the case of all four drugs. (5) The combination makes it possible to use much smaller doses of these agents with much better results, at least as far as the decrease of enzymic activity is concerned. This is very promising for clinical use of AP agents in cancer chemotherapy and IMS agents in transplantation especially of the heart and lungs, because combining these compounds with dB6 will make possible to use smaller doses over a longer period of time with greater effectiveness.(ABSTRACT TRUNCATED AT 250 WORDS)
对静息淋巴细胞培养物中丝氨酸羟甲基转移酶(SHMT)的测量表明,该酶的活性水平非常低。在促有丝分裂刺激的影响下,丝氨酸羟甲基转移酶的活性被诱导提高5至20倍。在培养物中同时加入4 - 脱氧吡哆醇(dB6,一种维生素B6辅酶的有效拮抗剂)和促有丝分裂原,会抑制SHMT的诱导。分别在培养物中加入四种抗增殖(AP)和免疫抑制(IMS)药物,即放线菌素、阿糖胞苷、天冬酰胺酶和环孢素,得到了以下观察结果。(1)AP和IMS药物会使促有丝分裂原诱导的SHMT活性降低。AP/IMS化合物的浓度越高,酶活性的降低幅度就越大。(2)当一种AP/IMS药物与dB6联合使用时,其对SHMT的影响会显著增强。(3)无效浓度的AP/IMS药物与dB6联合使用时会变得有效。(4)正如人们所预期的那样,观察到的SHMT活性变化在这四种药物的情况下并不相同。(5)这种联合使用使得可以使用小得多的剂量的这些药物,并且效果更好,至少就酶活性的降低而言是这样。这对于AP药物在癌症化疗以及IMS药物在心脏和肺移植等方面的临床应用非常有前景,因为将这些化合物与dB6联合使用将有可能在更长时间内使用更小的剂量并获得更高的疗效。(摘要截断于250字)